Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) filed an 8-K disclosing a capital raise that closed on 18 Jun 2025. The company entered into Securities Purchase Agreements with accredited investors for a best-efforts registered public offering consisting of (i) 14.31 million common shares, (ii) 13.69 million pre-funded warrants and (iii) 28 million five-year common warrants, all priced at a combined $0.25 per share (or $0.2499 when issued as a pre-funded warrant).
Key commercial terms
- Common Warrants: exercise price $0.25, immediately exercisable, expire five years from issuance.
- Pre-Funded Warrants: exercise price $0.0001, immediately exercisable until fully exercised.
- Placement Agent: H.C. Wainwright & Co. receives 7.0% cash fee on gross proceeds, up to $165,950 in expenses, and 1.12 million placement-agent warrants at $0.3125.
- Gross proceeds: approximately $6.3 million, before fees and expenses; additional proceeds possible upon warrant exercise.
Use of proceeds: fund the Phase 2 clinical trial of NGC-Cap and for general working capital.
Lock-up & issuance restrictions:
- No issuance of equity or equivalents for 60 days.
- No ATM, equity-line or variable-rate transactions for six months, except certain transactions with the Placement Agent after 90 days.
The securities were issued under the company’s effective S-1 (Reg. No. 333-287997). Exhibits include the forms of warrants, the purchase agreement and the related press release.
Investor takeaways: The raise strengthens near-term liquidity and advances a core clinical asset, but could increase the fully-diluted share count by up to ~57 million shares, representing meaningful dilution at a discounted price point.